Recent Updates
Recently added Catalysts
FTH Positive Sentiment

Faeth Therapeutics to Host Virtual KOL Event on Multi-Nodal Inhibition for the Treatment of Endometrial Cancer on October 6, 2026

Tuesday, September 8, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Faeth Therapeutics has announced a virtual key opinion leader event scheduled for October 6, 2026. The event will feature Dr. Marcus Goncalves from NYU Langone Health, who will discuss the PAM pathway in relation to endometrial cancer. This initiative highlights the company's commitment to advancing cancer treatment through expert collaboration.

Market Sentiment Analysis

POSITIVE FACTORS

  • Faeth Therapeutics is actively engaging with experts in the field.
  • The event aims to discuss innovative treatment approaches for endometrial cancer.
  • The involvement of a notable expert, Dr. Marcus Goncalves, adds credibility.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Cash runway
~35 mo
Minimal dilution risk
Lead asset
PAN-301-1
Phase 1 · Prostate Cancer

Full Press Release Details

AUSTIN, Texas--(BUSINESS WIRE)--Faeth Therapeutics (Nasdaq: FTH), a clinical-stage oncology company developing multi-node therapies for cancer patients, including its lead program PIKTOR, today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 6, 2026 at 10:00 AM ET featuring Marcus Goncalves, MD, PhD (NYU Langone Health & Scientific Co-founder, Faeth Therapeutics), who will join company management to discuss the PAM (PI3K/AKT/mTOR) pathway in human can

Frequently Asked Questions

What is the date of the Faeth Therapeutics KOL event?

The KOL event is scheduled for October 6, 2026.

Who will speak at the KOL event?

Dr. Marcus Goncalves will speak at the event.

What topic will be discussed during the event?

The discussion will focus on the PAM pathway in endometrial cancer.

What is Faeth Therapeutics known for?

Faeth Therapeutics develops multi-node therapies for cancer patients.

ShareAdd on Google
Tags: FTH Viatris Investor Conferences Healthcare Faeth Therapeutics endometrial cancer KOL event Marcus Goncalves oncology
Last updated: Sep 8, 2026

Biotech snapshot

Cash runway
$186M liquidity · $5M/mo burn
~35 mo
Minimal dilution risk
Lead asset
PAN-301-1Phase 1
Prostate Cancer →